- Home
- XOMAP vs ZTS Comparison
XOMAP vs ZTS Comparison
Compare XOMAP & ZTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XOMAP
- ZTS
- Stock Information
- Founded
- XOMAP N/A
- ZTS 1952
- Country
- XOMAP United States
- ZTS United States
- Employees
- XOMAP 13
- ZTS N/A
- Industry
- XOMAP Biotechnology: Pharmaceutical Preparations
- ZTS Biotechnology: Pharmaceutical Preparations
- Sector
- XOMAP Health Care
- ZTS Health Care
- Exchange
- XOMAP Nasdaq
- ZTS Nasdaq
- Market Cap
- XOMAP N/A
- ZTS N/A
- IPO Year
- XOMAP N/A
- ZTS 2013
- Fundamental
- Price
- XOMAP $25.84
- ZTS $164.65
- Analyst Decision
- XOMAP
- ZTS Strong Buy
- Analyst Count
- XOMAP 0
- ZTS 9
- Target Price
- XOMAP N/A
- ZTS $217.56
- AVG Volume (30 Days)
- XOMAP N/A
- ZTS 2.4M
- Earning Date
- XOMAP N/A
- ZTS 05-06-2025
- Dividend Yield
- XOMAP N/A
- ZTS 1.22%
- EPS Growth
- XOMAP N/A
- ZTS 7.89
- EPS
- XOMAP N/A
- ZTS 5.47
- Revenue
- XOMAP N/A
- ZTS $9,256,000,000.00
- Revenue This Year
- XOMAP N/A
- ZTS $1.77
- Revenue Next Year
- XOMAP N/A
- ZTS $6.60
- P/E Ratio
- XOMAP N/A
- ZTS $30.10
- Revenue Growth
- XOMAP N/A
- ZTS 8.33
- 52 Week Low
- XOMAP N/A
- ZTS $144.80
- 52 Week High
- XOMAP N/A
- ZTS $200.33
- Technical
- Relative Strength Index (RSI)
- XOMAP 55.97
- ZTS 49.95
- Support Level
- XOMAP $25.73
- ZTS $160.25
- Resistance Level
- XOMAP $25.93
- ZTS $165.41
- Average True Range (ATR)
- XOMAP 0.08
- ZTS 2.95
- MACD
- XOMAP 0.03
- ZTS 0.15
- Stochastic Oscillator
- XOMAP 78.77
- ZTS 84.44
About XOMAP XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.